FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)

Introduction:
In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated esketamine, a nasal spray for treatment-resistant depression (TRD). The discussion revolved around its efficacy, safety profile, and the implications of its fast-acting mechanism.

Key Points for Providers:

  1. Mechanism of Action:
    • Esketamine is an NMDA receptor antagonist offering rapid antidepressant effects. Its unique pathway targets glutamatergic systems, distinguishing it from traditional monoamine therapies.
  2. Clinical Data Review:
    • Trials demonstrated significant reductions in depressive symptoms within 24-48 hours of administration.
    • Response rates were particularly strong in patients with a high risk of suicide, though durability of response varied.
  3. Risk-Benefit Profile:
    • Side effects included dissociation, sedation, and transient increases in blood pressure, necessitating monitoring during administration.
    • The committee emphasized that esketamine should be administered in certified clinical settings under direct supervision.
  4. Regulatory Considerations:
    • Esketamine received Breakthrough Therapy Designation and was fast-tracked for review given the unmet need for TRD treatments.
    • FDA approval included a Risk Evaluation and Mitigation Strategy (REMS) to ensure safe use.

The VitalPoint for Providers:
Esketamine introduces a paradigm shift for TRD management with its rapid efficacy and novel mechanism. Providers must weigh its potential benefits against the need for careful monitoring and patient selection. Stay updated on its evolving real-world application and long-term safety data.

Further Resources:

  • FDA Meeting Document on Esketamine
  • FDA Drug Approval Process
    FDA (2019b). Psychopharmacologic drugs advisory committee (PDAC) and drug safety and risk management (DSaRM) advisory committee meeting; agenda topic: The committees will discuss the efficacy, safety, and risk-benefit profile of new drug application (NDA) 211243, esketamine 28 mg single-use nasal spray device, submitted by Janssen pharmaceuticals, inc., for the treatment of treatment-resistant depression. https://www.fda.gov/media/121376/download.
VitalPoint Technologies, Inc.

Disclaimer

None of the statements in this announcement or via any web sites linked herein have been evaluated by the FDA. Furthermore, none of the statements in this announcement or any web sites linked herein should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.

Scroll to Top